BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2021 5:56:26 AM | Browse: 418 | Download: 993
 |
Received |
|
2021-01-14 15:23 |
|
Peer-Review Started |
|
2021-01-14 15:24 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-10 22:51 |
|
Revised |
|
2021-02-28 07:54 |
|
Second Decision |
|
2021-04-02 08:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-05 17:17 |
|
Articles in Press |
|
2021-04-05 17:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-04-15 09:44 |
|
Publish the Manuscript Online |
|
2021-04-21 05:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatitis C virus micro-elimination: Where do we stand?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alessandra Mangia, Rosa Cotugno, Giovanna Cocomazzi, Maria Maddalena Squillante and Valeria Piazzolla |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alessandra Mangia, MD, Chief Doctor, Liver Unit, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, San Giovanni Rotondo 71013, Fg, Italy. a.mangia@tin.it |
| Key Words |
Hepatitis C virus antibodies; Hepatitis C virus elimination; Hepatitis C virus epidemiology; Hepatitis C virus RNA; Hepatitis C virus diagnosis; Hepatitis C virus infection |
| Core Tip |
Achievement of hepatitis C virus (HCV) elimination using direct-acting antiviral drugs treatment by 2030 promoted by World Health Organization is hardly attainable especially amidst the coronavirus disease 2019 pandemic. The smaller goal of eliminating HCV from population segments for which tailored strategies of prevention and treatment can be easily implemented appears more realistic. Different specific populations and at-risk groups, as well as different settings including prisons and hospitals have been selected for micro-elimination campaigns. Dedicated micro-elimination strategies have also been designed at geographical level according to the countries income and HCV epidemiology. The success of micro-elimination depends on reliable epidemiological data and active involvement of all the different stakeholders. |
| Publish Date |
2021-04-21 05:56 |
| Citation |
Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i16/1728.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i16.1728 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
